{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:31:01Z","timestamp":1793043061775,"version":"4.5.0"},"reference-count":100,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2022,3,1]]},"DOI":"10.1001\/jamadermatol.2021.4926","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T11:02:07Z","timestamp":1642590127000},"page":"300","source":"Crossref","is-referenced-by-count":62,"title":["Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa"],"prefix":"10.1001","volume":"158","author":[{"given":"Samuel","family":"Der Sarkissian","sequence":"first","affiliation":[{"name":"Department of Dermatology, Liverpool Hospital, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Schapoor","family":"Hessam","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joslyn S.","family":"Kirby","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Lowes","sequence":"additional","affiliation":[{"name":"Rockefeller University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dillon","family":"Mintoff","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mater Dei Hospital, Msida, Malta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley B.","family":"Naik","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California San Francisco"},{"name":"Associate Editor, JAMA Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Christian","family":"Ring","sequence":"additional","affiliation":[{"name":"Department of Dermato-Venereology & Wound Healing Centre, Bispebjerg Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha Suyien","family":"Chandran","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, National University Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Frew","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Liverpool Hospital, Sydney, Australia"},{"name":"University of New South Wales, Sydney, Australia"},{"name":"Laboratory of Translational Cutaneous Medicine, Ingham Institute of Applied Medical Research, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"drv210005r1","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","article-title":"Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis.","volume":"82","author":"Goldburg","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"drv210005r2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa.","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"drv210005r3","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/j.jaad.2015.07.055","article-title":"Systemic associations of hidradenitis suppurativa.","volume":"73","author":"Kohorst","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"drv210005r4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jid.2020.06.019","article-title":"A systematic review of promising therapeutic targets in hidradenitis suppurativa: a critical evaluation of mechanistic and clinical relevance.","volume":"141","author":"Frew","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"1","key":"drv210005r5","doi-asserted-by":"publisher","first-page":"12207","DOI":"10.1038\/s41598-019-48226-w","article-title":"Specimen collection for translational studies in hidradenitis suppurativa.","volume":"9","author":"Byrd","year":"2019","journal-title":"Sci Rep"},{"issue":"4","key":"drv210005r8","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","article-title":"Biomarkers in atopic dermatitis\u2014a review on behalf of the International Eczema Council.","volume":"147","author":"Renert-Yuval","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"drv210005r9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jclinepi.2012.01.006","article-title":"GRADE guidelines: 11. making an overall rating of confidence in effect estimates for a single outcome and for all outcomes.","volume":"66","author":"Guyatt","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"drv210005r10","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00403-018-1867-z","article-title":"Visfatin and insulin levels and cigarette smoking are independent risk factors for hidradenitis suppurativa: a case-control study.","volume":"310","author":"Akdogan","year":"2018","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"drv210005r11","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/bjd.15939","article-title":"Incidence of hidradenitis suppurativa among tobacco smokers: a population-based retrospective analysis in the USA.","volume":"178","author":"Garg","year":"2018","journal-title":"Br J Dermatol"},{"issue":"12","key":"drv210005r12","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jamadermatol.2020.3630","article-title":"Contribution of genetics to the susceptibility to hidradenitis suppurativa in a large, cross-sectional Dutch twin cohort.","volume":"156","author":"van Straalen","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"3","key":"drv210005r13","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jaad.2014.04.001","article-title":"Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity.","volume":"71","author":"Schrader","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"drv210005r14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000493465","article-title":"Adolescent-onset hidradenitis suppurativa: prevalence, risk factors and disease features.","volume":"235","author":"Molina-Leyva","year":"2019","journal-title":"Dermatology"},{"issue":"5","key":"drv210005r15","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/jdv.2018.32.issue-5","article-title":"Insulin resistance in hidradenitis suppurativa: a case-control study.","volume":"32","author":"Vilanova","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"drv210005r16","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/bjd.15441","article-title":"A systematic review and critical evaluation of reported pathogenic sequence variants in hidradenitis suppurativa.","volume":"177","author":"Frew","year":"2017","journal-title":"Br J Dermatol"},{"issue":"5","key":"drv210005r17","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1177\/1203475419852049","article-title":"Hidradenitis suppurativa: comprehensive review of predisposing genetic mutations and changes.","volume":"23","author":"Jfri","year":"2019","journal-title":"J Cutan Med Surg"},{"issue":"6","key":"drv210005r18","doi-asserted-by":"publisher","first-page":"736","DOI":"10.2340\/00015555-2061","article-title":"Chitinase-3-like protein 1 (YKL-40): novel biomarker of hidradenitis suppurativa disease activity?","volume":"95","author":"Matusiak","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"drv210005r19","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1111\/bjd.2013.168.issue-6","article-title":"Myeloid marker S100A8\/A9 and lymphocyte marker, soluble interleukin 2 receptor: biomarkers of hidradenitis suppurativa disease activity?","volume":"168","author":"Wieland","year":"2013","journal-title":"Br J Dermatol"},{"issue":"6","key":"drv210005r20","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1080\/13547500903075218","article-title":"Soluble interleukin-2 receptor serum level is a useful marker of hidradenitis suppurativa clinical staging.","volume":"14","author":"Matusiak","year":"2009","journal-title":"Biomarkers"},{"issue":"1","key":"drv210005r21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000505184","article-title":"Deranged iron status evidenced by iron deficiency characterizes patients with hidradenitis suppurativa.","volume":"236","author":"Ponikowska","year":"2020","journal-title":"Dermatology"},{"issue":"suppl 1","key":"drv210005r22","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1093\/ajcp\/aqz112.029","article-title":"Anemia in hidradenitis suppurativa, hepcidin as a diagnostic tool.","volume":"152","author":"Ghias","year":"2019","journal-title":"Am J Clin Pathol"},{"key":"drv210005r23","first-page":"18","article-title":"A composite biomarker score for the diagnosis of hidradenitis suppurativa","volume":"28","author":"Argyropoulou","year":"2019","journal-title":"Exp Dermatol"},{"issue":"6","key":"drv210005r24","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.jid.2018.11.018","article-title":"The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction.","volume":"139","author":"Witte-H\u00e4ndel","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"4","key":"drv210005r25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00403-019-02014-8","article-title":"Serum amyloid A and C-reactive protein levels and erythrocyte sedimentation rate are important indicators in hidradenitis suppurativa.","volume":"312","author":"Akdogan","year":"2020","journal-title":"Arch Dermatol Res"},{"key":"drv210005r26","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/2450401","article-title":"The clinical significance of increased serum proinflammatory cytokines, C-reactive protein, and erythrocyte sedimentation rate in patients with hidradenitis suppurativa.","volume":"2017","author":"Jim\u00e9nez-Gallo","year":"2017","journal-title":"Mediators Inflamm"},{"key":"drv210005r27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cyto.2017.12.020","article-title":"Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa.","volume":"103","author":"Jim\u00e9nez-Gallo","year":"2018","journal-title":"Cytokine"},{"issue":"8","key":"drv210005r28","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00403-019-02018-4","article-title":"Circulating levels of adiponectin, leptin, resistin and visfatin in non-diabetics patients with hidradenitis suppurativa.","volume":"312","author":"Gonz\u00e1lez-L\u00f3pez","year":"2020","journal-title":"Arch Dermatol Res"},{"issue":"6","key":"drv210005r29","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.abd.2020.04.009","article-title":"Serum irisin level, insulin resistance, and lipid profiles in patients with hidradenitis suppurativa: a case-control study.","volume":"95","author":"\u00d6zkur","year":"2020","journal-title":"An Bras Dermatol"},{"issue":"4","key":"drv210005r30","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jaad.2016.10.042","article-title":"Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: implications for treatment with anti-IL-17 agents.","volume":"76","author":"Matusiak","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"drv210005r31","first-page":"6","article-title":"DNA methylation and microRNA biomarkers for noninvasive detection of hidradenitis suppurativa","volume":"28","author":"Radhakrishna","year":"2019","journal-title":"Exp Dermatol"},{"issue":"2","key":"drv210005r32","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s10753-016-0492-2","article-title":"Expression of miRNA-155, miRNA-223, miRNA-31, miRNA-21, miRNA-125b, and miRNA-146a in the inflammatory pathway of hidradenitis suppurativa.","volume":"40","author":"Hessam","year":"2017","journal-title":"Inflammation"},{"issue":"9","key":"drv210005r33","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1001\/jamadermatol.2017.0904","article-title":"The follicular skin microbiome in patients with hidradenitis suppurativa and healthy controls.","volume":"153","author":"Ring","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"2","key":"drv210005r34","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/cid\/cix285","article-title":"The microbiological landscape of anaerobic infections in hidradenitis suppurativa: a prospective metagenomic study.","volume":"65","author":"Guet-Revillet","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"1","key":"drv210005r35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jid.2018.09.036","article-title":"Are bacteria infectious pathogens in hidradenitis suppurativa? debate at the Symposium for Hidradenitis Suppurativa Advances Meeting, November 2017.","volume":"139","author":"Naik","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"9","key":"drv210005r36","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1111\/jdv.v33.9","article-title":"The microbiome of tunnels in hidradenitis suppurativa patients.","volume":"33","author":"Ring","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"drv210005r37","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.jid.2019.06.151","article-title":"Loss of skin microbial diversity and alteration of bacterial metabolic function in hidradenitis suppurativa.","volume":"140","author":"Schneider","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"6","key":"drv210005r38","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1111\/bjd.2015.173.issue-6","article-title":"Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa.","volume":"173","author":"Kelly","year":"2015","journal-title":"Br J Dermatol"},{"issue":"2","key":"drv210005r39","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.4049\/jimmunol.0903907","article-title":"Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa.","volume":"186","author":"Wolk","year":"2011","journal-title":"J Immunol"},{"issue":"3","key":"drv210005r40","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1001\/jamadermatol.2017.5890","article-title":"A novel severity assessment scoring system for hidradenitis suppurativa.","volume":"154","author":"Hessam","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"9","key":"drv210005r41","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1016\/j.jid.2016.04.036","article-title":"Intrinsic defect in keratinocyte function leads to inflammation in hidradenitis suppurativa.","volume":"136","author":"Hotz","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"4","key":"drv210005r42","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/bjd.v182.4","article-title":"Interleukin 17C is elevated in lesional tissue of hidradenitis suppurativa.","volume":"182","author":"Navrazhina","year":"2020","journal-title":"Br J Dermatol"},{"issue":"6","key":"drv210005r43","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","article-title":"Elevated levels of tumour necrosis factor (TNF)-a, interleukin (IL)-1\u00df and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-a and IL-1\u00df.","volume":"164","author":"van der Zee","year":"2011","journal-title":"Br J Dermatol"},{"issue":"5","key":"drv210005r44","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1159\/000510689","article-title":"Serum concentration and skin expression of S100A7 (psoriasin) in patients suffering from hidradenitis suppurativa.","volume":"237","author":"Batycka-Baran","year":"2021","journal-title":"Dermatology"},{"issue":"5","key":"drv210005r45","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/bjd.2012.166.issue-5","article-title":"Immunohistological pointers to a possible role for excessive cathelicidin (LL-37) expression by apocrine sweat glands in the pathogenesis of hidradenitis suppurativa\/acne inversa.","volume":"166","author":"Emelianov","year":"2012","journal-title":"Br J Dermatol"},{"issue":"508","key":"drv210005r46","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav5908","article-title":"Neutrophil extracellular traps, B cells, and type I interferons contribute to immune dysregulation in hidradenitis suppurativa.","volume":"11","author":"Byrd","year":"2019","journal-title":"Sci Transl Med"},{"issue":"19","key":"drv210005r47","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139932","article-title":"Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF-a therapy.","volume":"5","author":"Lowe","year":"2020","journal-title":"JCI Insight"},{"issue":"2","key":"drv210005r48","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13232","article-title":"Relationship between fecal calprotectin level and disease activity in patients with hidradenitis suppurativa.","volume":"33","author":"Eser","year":"2020","journal-title":"Dermatol Ther"},{"issue":"1","key":"drv210005r49","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/pde.v38.1","article-title":"Prevalence of inflammatory bowel disease among pediatric patients with hidradenitis suppurativa and the potential role of screening with fecal calprotectin.","volume":"38","author":"Lloyd-McLennan","year":"2021","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"drv210005r50","first-page":"830","article-title":"Color Doppler as a tool for correlating vascularization and pain in hidradenitis suppurativa lesions.","volume":"25","author":"Nazzaro","year":"2019","journal-title":"Skin Res Technol"},{"issue":"4","key":"drv210005r51","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/bjd.v184.4","article-title":"Doppler ultrasound-based noninvasive biomarkers in hidradenitis suppurativa: evaluation of analytical and clinical validity.","volume":"184","author":"Grand","year":"2021","journal-title":"Br J Dermatol"},{"issue":"8","key":"drv210005r52","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1111\/jdv.2018.32.issue-8","article-title":"Power Doppler ultrasound assessment of vascularization in hidradenitis suppurativa lesions.","volume":"32","author":"Caposiena Caro","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"drv210005r53","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/jdv.14599","article-title":"Low and high body mass index in hidradenitis suppurativa patients-different subtypes?","volume":"32","author":"Theut Riis","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"drv210005r54","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.jaad.2015.08.052","article-title":"Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa (HS).","volume":"73","author":"Hessam","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"drv210005r55","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00403-019-02032-6","article-title":"Epicardial fat thickness is increased and associated with disease severity in hidradenitis suppurativa.","volume":"312","author":"Alatas","year":"2020","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"drv210005r56","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.jaad.2019.12.044","article-title":"Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: a post hoc analysis of PIONEER 1 and 2 individual patient data.","volume":"82","author":"Frew","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"drv210005r57","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/ced.v46.2","article-title":"Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab.","volume":"46","author":"Frew","year":"2021","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"drv210005r58","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jid.2019.06.152","article-title":"A genetic variant in the BCL2 gene associates with adalimumab response in hidradenitis suppurativa clinical trials and regulates expression of BCL2.","volume":"140","author":"Liu","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"10","key":"drv210005r59","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1016\/j.jid.2019.10.025","article-title":"Low prevalence of GSC gene mutations in a large cohort of predominantly Caucasian patients with hidradenitis suppurativa.","volume":"140","author":"Duchatelet","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"3","key":"drv210005r60","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/bjd.v185.3","article-title":"Differential profiles of gamma secretase Notch signalling in hidradenitis suppurativa: the need for genotype-endotype-phenotype analysis.","volume":"185","author":"Frew","year":"2021","journal-title":"Br J Dermatol"},{"issue":"9","key":"drv210005r61","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1111\/exd.v29.9","article-title":"Association of retinol binding protein4 (RBP4) and ghrelin plasma levels with insulin resistance and disease severity in non-diabetic patients with hidradenitis suppurativa.","volume":"29","author":"Gonz\u00e1lez-L\u00f3pez","year":"2020","journal-title":"Exp Dermatol"},{"issue":"4","key":"drv210005r62","first-page":"410","article-title":"Association of TLR polymorphisms with susceptibility to hidradenitis suppurativa in a Spanish Caucasian population","volume":"95","author":"Ocejo-Vinyals","year":"2020","journal-title":"HLA"},{"issue":"7","key":"drv210005r63","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jamadermatol.2020.1047","article-title":"Association of birth weight, childhood body mass index, and height with risk of hidradenitis suppurativa.","volume":"156","author":"J\u00f8rgensen","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"7","key":"drv210005r64","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1001\/jamadermatol.2020.1281","article-title":"Disease trajectories for hidradenitis suppurativa in the Danish population.","volume":"156","author":"Kj\u00e6rsgaard Andersen","year":"2020","journal-title":"JAMA Dermatol"},{"key":"drv210005r65","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2147\/JMDH.S104807","article-title":"Information bias in health research: definition, pitfalls, and adjustment methods.","volume":"9","author":"Althubaiti","year":"2016","journal-title":"J Multidiscip Healthc"},{"issue":"2","key":"drv210005r66","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000431175","article-title":"Hidradenitis suppurativa\/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation.","volume":"231","author":"Zouboulis","year":"2015","journal-title":"Dermatology"},{"issue":"1","key":"drv210005r67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.det.2015.08.009","article-title":"Diagnosing hidradenitis suppurativa.","volume":"34","author":"Revuz","year":"2016","journal-title":"Dermatol Clin"},{"issue":"3","key":"drv210005r68","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/bjd.14214","article-title":"Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa.","volume":"174","author":"Lima","year":"2016","journal-title":"Br J Dermatol"},{"issue":"6","key":"drv210005r69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130522","article-title":"Compartmentalized cytokine responses in hidradenitis suppurativa.","volume":"10","author":"Kanni","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"drv210005r70","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1365-2133.2011.10698.x","article-title":"Adalimumab (antitumour necrosis factor-a) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study.","volume":"166","author":"van der Zee","year":"2012","journal-title":"Br J Dermatol"},{"issue":"2","key":"drv210005r71","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/exd.2018.27.issue-2","article-title":"Elevated levels of the antimicrobial peptide LL-37 in hidradenitis suppurativa are associated with a Th1\/Th17 immune response.","volume":"27","author":"Thomi","year":"2018","journal-title":"Exp Dermatol"},{"issue":"8","key":"drv210005r72","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1128\/CVI.00152-14","article-title":"Cytokine production assays reveal discriminatory immune defects in adults with recurrent infections and noninfectious inflammation.","volume":"21","author":"Ten Oever","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"drv210005r73","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3389\/fmed.2019.00253","article-title":"A scoping review of non-invasive imaging modalities in dermatological disease: potential novel biomarkers in hidradenitis suppurativa.","volume":"6","author":"Grand","year":"2019","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"drv210005r74","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1111\/dsu.12329","article-title":"Ultrasound in-depth characterization and staging of hidradenitis suppurativa.","volume":"39","author":"Wortsman","year":"2013","journal-title":"Dermatol Surg"},{"issue":"11","key":"drv210005r75","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1111\/jdv.v33.11","article-title":"Ultrasound as a diagnostic and management tool in hidradenitis suppurativa patients: a multicentre study.","volume":"33","author":"Martorell","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"drv210005r76","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jdin.2020.09.005","article-title":"Quantifying the natural variation in lesion counts over time in untreated hidradenitis suppurativa: implications for outcome measures and trial design.","volume":"1","author":"Frew","year":"2020","journal-title":"JAAD Int"},{"issue":"1","key":"drv210005r77","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jaad.2016.08.036","article-title":"Interleukin 6 and high-sensitivity C-reactive protein are potential predictive markers of response to infliximab in hidradenitis suppurativa.","volume":"76","author":"Montaudi\u00e9","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"19","key":"drv210005r78","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139930","article-title":"Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis.","volume":"5","author":"Gudjonsson","year":"2020","journal-title":"JCI Insight"},{"issue":"5","key":"drv210005r79","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa.","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"drv210005r80","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2018.05.040","article-title":"Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa\/acne inversa: 3-year results of a phase 3 open-label extension study.","volume":"80","author":"Zouboulis","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"drv210005r81","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1016\/j.jid.2019.07.682","article-title":"Research techniques made simple: feature selection for biomarker discovery.","volume":"139","author":"Torres","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"1","key":"drv210005r82","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jdin.2020.05.005","article-title":"Hidradenitis suppurativa is an autoinflammatory keratinization disease: a review of the clinical, histologic, and molecular evidence.","volume":"1","author":"Frew","year":"2020","journal-title":"JAAD Int"},{"issue":"1","key":"drv210005r83","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/jdv.v35.1","article-title":"Increased expression profile of NCSTN, Notch and PI3K\/AKT3 in hidradenitis suppurativa.","volume":"35","author":"Hessam","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"drv210005r84","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/bjd.14223","article-title":"Nicastrin mutations in familial acne inversa impact keratinocyte proliferation and differentiation through the Notch and phosphoinositide 3-kinase\/AKT signalling pathways.","volume":"174","author":"Xiao","year":"2016","journal-title":"Br J Dermatol"},{"issue":"1","key":"drv210005r85","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1046\/j.1365-2133.2003.05390.x","article-title":"Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa.","volume":"149","author":"Sartorius","year":"2003","journal-title":"Br J Dermatol"},{"issue":"5","key":"drv210005r86","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/bjd.2017.177.issue-5","article-title":"Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity.","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br J Dermatol"},{"issue":"5","key":"drv210005r87","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/bjd.v184.5","article-title":"Hidradenitis Suppurativa Area and Severity Index Revised (HASI-R): psychometric property assessment.","volume":"184","author":"Goldfarb","year":"2021","journal-title":"Br J Dermatol"},{"issue":"6","key":"drv210005r88","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/j.jaci.2020.12.651","article-title":"Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa.","volume":"147","author":"Navrazhina","year":"2021","journal-title":"J Allerg Clin Immunol"},{"issue":"9","key":"drv210005r89","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/j.jid.2021.02.742","article-title":"In-depth analysis of the hidradenitis suppurativa serum proteome identifies distinct inflammatory subtypes.","volume":"141","author":"Navrazhina","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"1","key":"drv210005r90","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/bjd.v183.1","article-title":"Clinical efficacy of complement C5a inhibition by IFX-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab.","volume":"183","author":"Giamarellos-Bourboulis","year":"2020","journal-title":"Br J Dermatol"},{"issue":"4","key":"drv210005r92","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jid.2018.10.020","article-title":"Apocrine gland-rich skin has a non-inflammatory IL-17-related immune milieu, that turns to inflammatory IL-17-mediated disease in hidradenitis suppurativa.","volume":"139","author":"Jenei","year":"2019","journal-title":"J Invest Dermatol"},{"key":"drv210005r93","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3389\/fimmu.2018.00424","article-title":"Immunotopographical differences of human skin.","volume":"9","author":"B\u00e9ke","year":"2018","journal-title":"Front Immunol"},{"issue":"6","key":"drv210005r94","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1111\/bjd.v181.6","article-title":"Defining lesional, perilesional and unaffected skin in hidradenitis suppurativa: proposed recommendations for clinical trials and translational research studies.","volume":"181","author":"Frew","year":"2019","journal-title":"Br J Dermatol"},{"issue":"4","key":"drv210005r95","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1001\/jamadermatol.2020.5467","article-title":"Global harmonization of morphological definitions in hidradenitis suppurativa for a proposed glossary.","volume":"157","author":"Frew","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"4","key":"drv210005r96","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/bjd.v185.4","article-title":"Potential predictive biomarkers of adalimumab response in patients with hidradenitis suppurativa.","volume":"185","author":"Cao","year":"2021","journal-title":"Br J Dermatol"},{"key":"drv210005r97","article-title":"Cutaneous squamous cell carcinoma arising in hidradenitis suppurativa: a case report.","volume":"7","author":"Roy","year":"2019","journal-title":"SAGE Open Med Case Rep"},{"issue":"6","key":"drv210005r98","first-page":"730","article-title":"Incidence of cancer among patients with hidradenitis suppurativa.","volume":"137","author":"Lapins","year":"2001","journal-title":"Arch Dermatol"},{"issue":"7","key":"drv210005r99","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/ced.v45.7","article-title":"Malignancy and infection risk during adalimumab therapy in hidradenitis suppurativa.","volume":"45","author":"Frew","year":"2020","journal-title":"Clin Exp Dermatol"},{"issue":"9","key":"drv210005r100","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1001\/jamadermatol.2019.1105","article-title":"A call to accelerate hidradenitis suppurativa research and improve care\u2014moving beyond burden.","volume":"155","author":"Naik","year":"2019","journal-title":"JAMA Dermatol"},{"key":"drv210005r6","unstructured":"Amur? A. Biomarker terminology: speaking the same language. US Food and Drug Administration. Accessed October 12, 2020. https:\/\/www.fda.gov\/files\/BIOMARKER-TERMINOLOGY--SPEAKING-THE-SAME-LANGUAGE.pdf"},{"key":"drv210005r7","unstructured":"Biomarker. European Medicines Agency. Accessed October 12, 2020. https:\/\/www.ema.europa.eu\/en\/glossary\/biomarker#:~:text=A%20biological%20molecule%20found%20in,European%20Medicines%20Agency"},{"key":"drv210005r91","unstructured":"ChemoCentryx announces positive topline results of phase II AURORA clinical trial of avacopan in the treatment of hidradenitis suppurativa (HS). News release. Accessed March 1, 2021. https:\/\/ir.chemocentryx.com\/news-releases\/news-release-details\/chemocentryx-announces-positive-topline-results-phase-ii-aurora"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2787957\/jamadermatology_der_sarkissian_2022_rv_210005_1649784382.47162.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T11:14:08Z","timestamp":1649848448000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2787957"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2021.4926","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,1]]}}}